• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session

    7/31/23 3:30:12 PM ET
    $ACAX
    $ACHR
    $AFRM
    $AIXI
    Other Pharmaceuticals
    Health Care
    Aerospace
    Industrials
    Get the next $ACAX alert in real time by email

    Gainers

    • Yellow Corporation (NASDAQ:YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report.
    • FOXO Technologies Inc. (NYSE:FOXO) rose 64.7% to $0.2232.
    • Bruush Oral Care Inc. (NASDAQ:BRSH) gained 48% to $0.1979 after the company announced a 1-for-25 reverse stock split.
    • Archer Aviation Inc. (NASDAQ:ACHR) shares climbed 41.8% to $6.78 after the company entered into contracts with the US Air Force with a total value of up to $142 million.
    • Tupperware Brands Corporation (NYSE:TUP) gained 39.6% to $4.2999 amid possible short squeeze interest.
    • Mallinckrodt plc (NYSE:MNK) jumped 39% to $1.51 on continued volatility following last week's reports of the company considering bankruptcy as part of a plan to avoid opioid payments.
    • GoodRx Holdings, Inc. (NASDAQ:GDRX) gained 38.1% to $9.32 after TD Cowen upgraded the stock from Market Perform to Outperform and raised its price target from $6.5 to $12.
    • AEye, Inc. (NASDAQ:LIDR) gained 34.6% to $0.3766.
    • Symbotic Inc. (NASDAQ:SYM) climbed 32.3% to $55.81 after the company reported better-than-expected third-quarter results.
    • Steakholder Foods Ltd. (NASDAQ:STKH) gained 30.6% to $1.53.
    • T2 Biosystems, Inc. (NASDAQ:TTOO) gained 28% to $0.1492 after the company announced it received an extension to comply with the Nasdaq listing requirements.
    • Xiao-I Corporation (NASDAQ:AIXI) gained 26.2% to $9.02.
    • iClick Interactive Asia Group Limited (NASDAQ:ICLK) climbed 25.8% to $3.0074.
    • Fifth Wall Acquisition Corp. III (NASDAQ:FWAC) climbed 25.6% to $14.48.
    • Applied Therapeutics, Inc. (NASDAQ:APLT) gained 25.4% to $1.8684.
    • Xiao-I Corporation (NASDAQ:AIXI) rose 24.3% to $8.89.
    • China Natural Resources, Inc. (NASDAQ:CHNR) shares surged 22.8% to $2.42 after the company agreed to sell all outstanding shares of Precise Space-Time Technology Limited to Feishang Group Limited, together with PSTT's outstanding payable owed to the Company, for consideration of around RMB95,761,119 in cash.
    • Nikola Corporation (NASDAQ:NKLA) gained 21.1% to $2.7520. The company announced an agreement in which J.B. Hunt Transport will purchase 13 Nikola zero-emission Class 8 EV trucks.
    • Innoviz Technologies Ltd. (NASDAQ:INVZ) climbed 21.1% to $4.1291 amid bullish commentary from a well-known short seller.
    • SoFi Technologies, Inc. (NASDAQ:SOFI) gained 20.4% to $11.49 after the company reported better-than-expected Q2 financial results, issued 2H adjusted net revenue guidance and raised FY23 adjusted net revenue guidance.
    • Canoo Inc. (NASDAQ:GOEV) climbed 18.6% to $0.6429.
    • fuboTV Inc. (NASDAQ:FUBO) gained 18% to $3.3150.
    • 2U, Inc. (NASDAQ:TWOU) gained 15.5% to $4.72.
    • Barnes & Noble Education, Inc. (NYSE:BNED) shares climbed 15.2% to $1.44 after the company entered into an agreement with key financial stakeholders and strategic partners to strengthen financial position and support growth initiatives.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) climbed 14.5% to $0.2947.
    • Jumia Technologies AG (NASDAQ:JMIA) rose 14% to $4.87.
    • New Relic, Inc. (NYSE:NEWR) gained 13.5% to $84.03 after the company reported better-than-expected Q1 financial results and announced it will be acquired by Francisco Partners and TPG for $6.5 billion.
    • TMC the metals company Inc. (NASDAQ:TMC) gained 13.4% to $1.6450.
    • Novavax, Inc. (NASDAQ:NVAX) rose 13% to $9.26.
    • AnaptysBio, Inc. (NASDAQ:ANAB) gained 13% to $19.34. AnaptysBio, said that GSK has received U.S. Food and Drug Administration approval for JEMPERLI (dostarlimab-gxly) plus carboplatin and paclitaxel (chemotherapy) for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer.
    • Eos Energy Enterprises, Inc. (NASDAQ:EOSE) rose 12.2% to $2.5350. Eos Energy Enterprises said it expects to record revenue of $0.2 million for the quarter ended June 30, 2023.
    • iHeartMedia, Inc. (NASDAQ:IHRT) gained 11.5% to $4.6950.
    • Affirm Holdings, Inc. (NASDAQ:AFRM) rose 11.2% to $19.20.
    • Palantir Technologies Inc. (NYSE:PLTR) climbed 10.1% to $19.61 on continued upward momentum after Wedbush on Friday initiated coverage on the stock with an Outperform rating and announced a $25 price target.
    • Aurora Acquisition Corp. (NASDAQ:AURC) gained 9.9% to $48.36 after jumping 113% on Friday
    • Roku, Inc. (NASDAQ:ROKU) gained 7.5% to $96.41 on continued strength after the company last week reported better-than-expected Q2 results and issued strong Q3 guidance.
    • AMC Entertainment Holdings, Inc. (NYSE:AMC) rose 7.1% to $19.61 after the company announced record admissions revenue for the week of July 21-27.
    • BlackBerry Limited (NYSE:BB) climbed 6.3% to $5.05.

    Losers

    • Alset Capital Acquisition Corp. (NASDAQ:ACAX) shares fell 27.9% to $5.50.
    • View, Inc. (NASDAQ:VIEW) dipped 26.5% to $10.58.
    • BioNexus Gene Lab Corp. (NASDAQ:BGLC) fell 25.3% to $2.24 after jumping over 40% on Friday.
    • Unique Fabricating, Inc. (NYSE:UFAB) fell 24.7% to $0.2601 after gaining 60% on Friday.
    • Silicom Ltd. (NASDAQ:SILC) dropped 24.6% to $29.45 after the company reported lower-than-expected second-quarter results.
    • Birks Group Inc. (NYSE:BGI) fell 20.1% to $3.3172.
    • Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) fell 18.8% to $26.00 after the company reported quarterly financial results.
    • Marker Therapeutics, Inc. (NASDAQ:MRKR) declined 18.7% to $5.26.
    • Tigo Energy, Inc. (NASDAQ:TYGO) fell 17.8% to $20.50.
    • TeraWulf Inc. (NASDAQ:WULF) declined 14.3% to $2.9288.
    • Femasys Inc. (NASDAQ:FEMY) fell 13% to $0.5655 after dipping over 22% on Friday.
    • Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) fell 11.3% to $0.9936 after the company received FDA Complete Response Letter for Lymphir (Denileukin Diftitox) for relapsed/refractory cutaneous T-cell lymphoma.
    • XPeng Inc. (NYSE:XPEV) dropped 11% to $20.82 after UBS downgraded the stock from Buy to Neutral.
    • Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) fell 10.4% to $0.0849 after the company announced NYSE American has commenced delisting proceedings and the company intends to appeal.
    • Pulse Biosciences, Inc. (NASDAQ:PLSE) fell 7.4% to $8.00.
    • Bel Fuse Inc. (NASDAQ:BELFB) fell 7.1% to $53.47.
    • DexCom, Inc. (NASDAQ:DXCM) declined 5.7% to $124.62 amid a pullback in the stock following earlier strength.

     

    Now Read This: Huntsman Likely To Post Sharp Decline In Q2 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

    Get the next $ACAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAX
    $ACHR
    $AFRM
    $AIXI

    CompanyDatePrice TargetRatingAnalyst
    FuboTV Inc.
    $FUBO
    3/27/2026$18.00Buy
    B. Riley Securities
    DexCom Inc.
    $DXCM
    3/24/2026$90.00In-line → Outperform
    Evercore ISI
    TeraWulf Inc.
    $WULF
    3/23/2026$30.00Buy
    Arete
    XPeng Inc.
    $XPEV
    3/23/2026$19.00Outperform → Neutral
    Macquarie
    SoFi Technologies Inc.
    $SOFI
    3/19/2026$19.00Equal Weight
    Wells Fargo
    Apellis Pharmaceuticals Inc.
    $APLS
    3/13/2026$31.00Buy
    Roth Capital
    Affirm Holdings Inc.
    $AFRM
    3/5/2026$82.00Buy
    BofA Securities
    Palantir Technologies Inc.
    $PLTR
    2/27/2026$150.00Buy
    Rosenblatt
    More analyst ratings

    $ACAX
    $ACHR
    $AFRM
    $AIXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on fuboTV with a new price target

    B. Riley Securities initiated coverage of fuboTV with a rating of Buy and set a new price target of $18.00

    3/27/26 8:48:55 AM ET
    $FUBO
    Movies/Entertainment
    Consumer Discretionary

    Dexcom upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Dexcom from In-line to Outperform and set a new price target of $90.00

    3/24/26 9:07:04 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Arete initiated coverage on TeraWulf with a new price target

    Arete initiated coverage of TeraWulf with a rating of Buy and set a new price target of $30.00

    3/23/26 8:29:37 AM ET
    $WULF
    EDP Services
    Technology

    $ACAX
    $ACHR
    $AFRM
    $AIXI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACAX
    $ACHR
    $AFRM
    $AIXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Kaiser Yaron

    3 - Steakholder Foods Ltd. (0001828098) (Issuer)

    3/27/26 11:01:00 AM ET
    $STKH
    Packaged Foods
    Consumer Staples

    SEC Form 4 filed by Shesky Craig

    4 - TMC the metals Co Inc. (0001798562) (Issuer)

    3/26/26 7:18:06 PM ET
    $TMC
    Metal Mining
    Basic Materials

    SEC Form 4 filed by Prager Paul B.

    4 - TERAWULF INC. (0001083301) (Issuer)

    3/25/26 8:00:24 PM ET
    $WULF
    EDP Services
    Technology

    $ACAX
    $ACHR
    $AFRM
    $AIXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

    Inclusive of $80 million in proceeds from private placement by leading investorsFirst Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB) today announced that its planned spin-off, First Tracks Biotherapeutics, Inc. ("First Tracks Bio"), and EcoR1 Capital (the "Selling Stockholder") have entered into a purchase agreement with certain third-party investors for a $145 million private placement, before deducting placement agent fees and other expenses. In the transaction, First Tracks Bio is selling an aggregate of 5,791,478 shares of First Tracks Bio's common stock (the "Primary Sha

    3/27/26 9:00:00 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

    Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-marketStockholders will receive one share of First Tracks Bio common stock for every one share of AnaptysBio common stock ownedFirst Tracks Bio initial cash balance of $180 million, inclusive of $80 million from private placement SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB) today announced that its Board of Directors has approved the previously announced spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks Bio"). The new company is expected to begin "regular-way" trading on the Nasdaq Stock Market LLC ("Nasdaq") on April 20, 2026, under the

    3/27/26 9:00:00 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

    Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value to shareholders, as well as an initial ~$140-$145 million in net cash and investmentsSusannah Gray, former CFO of Royalty Pharma, appointed to Anaptys' Board of Directors SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB) today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the company may repurchase up to $100,000,000 of the company's outstanding comm

    3/27/26 9:00:00 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAX
    $ACHR
    $AFRM
    $AIXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Noto Anthony bought $500,516 worth of shares (28,900 units at $17.32), increasing direct ownership by 0.25% to 11,704,352 units (SEC Form 4)

    4 - SoFi Technologies, Inc. (0001818874) (Issuer)

    3/17/26 4:05:47 PM ET
    $SOFI
    Finance: Consumer Services
    Finance

    Director Bucella Michael C. bought $19,950 worth of shares (1,338 units at $14.91), increasing direct ownership by 0.49% to 273,552 units (SEC Form 4)

    4 - TERAWULF INC. (0001083301) (Issuer)

    3/13/26 5:49:13 PM ET
    $WULF
    EDP Services
    Technology

    Director Urban David bought $100,100 worth of shares (16,250 units at $6.16), increasing direct ownership by 35% to 62,471 units (SEC Form 4)

    4 - Eos Energy Enterprises, Inc. (0001805077) (Issuer)

    3/10/26 8:52:43 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    $ACAX
    $ACHR
    $AFRM
    $AIXI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Palantir Technologies Inc.

    SCHEDULE 13G/A - Palantir Technologies Inc. (0001321655) (Subject)

    3/27/26 11:19:51 AM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Novavax Inc.

    SCHEDULE 13G/A - NOVAVAX INC (0001000694) (Subject)

    3/27/26 11:06:41 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by iHeartMedia Inc.

    SCHEDULE 13G/A - iHeartMedia, Inc. (0001400891) (Subject)

    3/27/26 9:55:30 AM ET
    $IHRT
    Broadcasting
    Consumer Discretionary

    $ACAX
    $ACHR
    $AFRM
    $AIXI
    Leadership Updates

    Live Leadership Updates

    View All

    Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

    Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value to shareholders, as well as an initial ~$140-$145 million in net cash and investmentsSusannah Gray, former CFO of Royalty Pharma, appointed to Anaptys' Board of Directors SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB) today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the company may repurchase up to $100,000,000 of the company's outstanding comm

    3/27/26 9:00:00 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eos Energy Enterprises Appoints Nathaniel Fick to Board of Directors

    PITTSBURGH, March 26, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ:EOSE) ("Eos" or the "Company"), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS), today announced the appointment of Nathaniel (Nate) Fick to its Board of Directors as an independent Common Class III director, effective March 24, 2026. Fick brings extensive leadership experience spanning national security, technology, cybersecurity, artificial intelligence (AI), and complex infrastructure—capabilities increasingly relevant as energy storage becomes embedded in critical grid operations. Fick currently

    3/26/26 8:45:00 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

    Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer Strengthened manufacturing capabilities through collaboration with Cellipont Bioservices and expanded Board of Directors with appointment of Kathryn Penkus Corzo HOUSTON, March 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, today a

    3/18/26 5:31:30 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAX
    $ACHR
    $AFRM
    $AIXI
    Financials

    Live finance-specific insights

    View All

    The Metals Company Announces Fourth Quarter and Full Year 2025 Corporate Update Conference Call for Friday, March 27, 2026

    NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- TMC the metals company Inc. (NASDAQ:TMC) ("TMC" or the "Company"), a leading developer of the world's largest estimated undeveloped resource of critical metals essential to energy, defense, manufacturing and infrastructure, today announced that it will host a conference call on Friday, March 27, 2026, to provide an update on fourth quarter and full year 2025 financial results and recent corporate developments.  Fourth Quarter and Full Year 2025 Conference Call Details  Date:Friday, March 27, 2026  Time:08:00 a.m. ET  Audio-only Dial-in:Register Here  Virtual webcast with slides:Register Here   The virtual webcast will be available for replay in

    3/20/26 8:00:00 AM ET
    $TMC
    Metal Mining
    Basic Materials

    XPENG Reports Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

    The Company achieved a positive net profit of RMB0.38 billion in the fourth quarter of 2025, recorded a positive net profit for a single quarter for the first time.Cash position[i] was RMB47.66 billion (US$6.81 billion) as of December 31, 2025Quarterly total revenues were RMB22.25 billion, a 38.2% increase year-over-yearQuarterly gross margin was 21.3%, an increase of 6.9 percentage points over the same period of 2024Quarterly vehicle margin was 13.0%, an increase of 3.0 percentage points over the same period of 2024Full year vehicle deliveries reached 429,445, a 125.9% increase year-over-yearFull year revenues reached RMB76.72 billion, an 87.7% increase year-over-yearFull year gross margin

    3/20/26 5:00:00 AM ET
    $XPEV
    Auto Manufacturing
    Industrials

    AEye Reports Fourth Quarter and Full-Year 2025 Results; Strengthened Foundation for Commercial Growth

    Revenue Doubled in Q4 over Q3; 40% Commercial Pipeline Expansion; 33% Increase in Customer Count Joining NVIDIA Halos AI Systems Inspection Lab; Demonstrated Apollo™ Lidar with NVIDIA DRIVE AGX Thor™ Operational Runway Into 2028 AEye, Inc. (NASDAQ:LIDR) (the "Company"), a global leader in software-defined, high-performance lidar solutions, today announced financial results for the fourth quarter and full year ended December 31, 2025. Business Highlights NVIDIA Ecosystem Maturity: Joining NVIDIA Halos AI Systems Inspection Lab to bolster automotive product readiness and demonstrated Apollo™ lidar with the NVIDIA DRIVE AGX Thor™ platform, the future centralized brain of NVIDIA-equi

    3/16/26 4:35:00 PM ET
    $LIDR
    Auto Parts:O.E.M.
    Consumer Discretionary

    $ACAX
    $ACHR
    $AFRM
    $AIXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Eos Energy Enterprises Inc.

    SC 13D/A - Eos Energy Enterprises, Inc. (0001805077) (Subject)

    12/17/24 2:48:02 PM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SC 13D/A filed by iClick Interactive Asia Group Limited

    SC 13D/A - iClick Interactive Asia Group Ltd (0001697818) (Subject)

    12/11/24 7:11:44 AM ET
    $ICLK
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by Citius Pharmaceuticals Inc.

    SC 13D/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

    11/27/24 4:05:31 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care